Table 1.
Strain | Host | Year | Truncation in receptor-binding motif | Residue 442 | Residue 472 | Residue 479 | Residue 480 | Residue 487 |
---|---|---|---|---|---|---|---|---|
hTor02 | Human | 2002–2003 | No | Tyr | Leu | Asn | Asp | Thr |
cSz02 | Civet | 2002–2003 | No | Tyr | Leu | Lys | Asp | Ser |
hcGd03 | Human and civet | 2003–2004 | No | Tyr | Pro | Asn | Gly | Ser |
cHb05 | Civet | 2005 | No | Tyr | Pro | Arg | Gly | Ser |
hHae08 | Human | 2008 | No | Phe | Phe | Asn | Asp | Ser |
hOptimize | Human | In vitro design | No | Phe | Phe | Asn | Asp | Ser |
cOptimize | Civet | In vitro design | No | Tyr | Pro | Arg | Gly | Thr |
bHKU3 | Bat | 2005 | Yes | Ser | Gly | Ser | Thr | Val |
bWIV1 | Bat | 2013 | No | Ser | Phe | Asn | Asp | Asn |
bRsSHC014 | Bat | 2013 | No | Trp | Pro | Arg | Pro | Ala |
Data from Hu et al. 2012 (ref.83). SARS-CoV, severe acute respiratory syndrome coronavirus.